ABT - Abbott Laboratories
70.73 0.00 (0.00%)
After hours: 5:34PM EST
| Previous Close | 69.41 |
| Open | 68.93 |
| Bid | 70.01 x 800 |
| Ask | 70.73 x 3100 |
| Day's Range | 67.94 - 70.75 |
| 52 Week Range | 54.32 - 74.15 |
| Volume | 6,802,348 |
| Avg. Volume | 6,248,758 |
| Market Cap | 124.225B |
| Beta (3Y Monthly) | 1.50 |
| PE Ratio (TTM) | 142.03 |
| EPS (TTM) | 0.50 |
| Earnings Date | Jan 22, 2019 - Jan 28, 2019 |
| Forward Dividend & Yield | 1.12 (1.54%) |
| Ex-Dividend Date | 2018-10-12 |
| 1y Target Est | 78.94 |
- CNBC Videos•3 days ago
Chartmaster says amid the market sell-off these are the b...
Carter Worth, Cornerstone Macro, on quality bear-market stocks to buy. With CNBC's Joe Kernen and the Fast Money traders, Pete Najarian, Steve Grasso, Brian Kelly and Tim Seymour.
- PR Newswire•10 hours ago
New Approvals Allow Chronic Pain Sufferers to Try Abbott's Non-Opioid Pain Therapy Before Getting Device Implant
ABBOTT PARK, Ill., Nov. 15, 2018 /PRNewswire/ -- Abbott (ABT) today announced the launch of the new DRG Invisible Trial System, which is approved by the U.S. Food and Drug Administration (FDA) and received CE Mark in Europe. People battling complex chronic pain conditions can now use the DRG Invisible Trial System to try Abbott's dorsal root ganglion (DRG) stimulation—a clinically proven, non-opioid treatment option for targeted chronic pain management.
- Zacks•yesterday
Abbott (ABT) Stock Moves -0.12%: What You Should Know
Abbott (ABT) closed at $69.41 in the latest trading session, marking a -0.12% move from the prior day.
- PR Newswire•yesterday
Abbott Recommends Rejection of Below-Market Mini-Tender Offer by Baker Mills LLC
ABBOTT PARK, Ill., Nov. 14, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing ...
Market Realist•2 days agoInside General Electric’s Healthcare Business Unit Spin-Off Plan
As part of its major restructuring plan, General Electric (GE) intends to spin off its Healthcare segment and turn it into a standalone entity. The company has planned the spin-off in a manner that maximizes shareholder wealth.
Markit•2 days agoSee what the IHS Markit Score report has to say about Abbott Laboratories.
Abbott Laboratories NYSE:ABT
- Investing.com•3 days ago
Abbott Labs Falls 3%
Investing.com - Abbott Labs (NYSE:ABT) fell by 3.04% to trade at $70.58 by 13:43 (18:43 GMT) on Monday on the NYSE exchange.
- Zacks•3 days ago
Surmodics' (SRDX) Q4 Earnings and Revenues Beat Estimates
Surmodics (SRDX) sees solid segmental performance in fiscal Q4; gains from alliance with Abbott.
GuruFocus.com•6 days agoYacktman Asset Management Buys 4 Companies in 3rd Quarter
New buys include Tepper’s Micron Technology and Post-It notes parent 3M
- Reuters•6 days ago
FOCUS-U.S. regulators snip red tape for medical devices to curb opioid crisis
Laura Perryman expected her medical company, Stimwave Technologies Inc, would have to wait several years for its painkilling device to win U.S. approval as a treatment for chronic migraines. When President Donald Trump declared a public health emergency over the abuse of heavy-duty painkillers like oxycodone and hydrocodone, he ordered all government agencies to take action in response to the death of 70,000 Americans last year from drug overdoses. The FDA told Reuters it has received over 200 submissions from companies seeking a speedy approval process for their devices.
Market Realist•6 days agoHow Analysts View Alexion Stock
In November 2018, of the total 18 analysts covering Alexion Pharmaceuticals (ALXN), 16 analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating. The mean rating for Alexion Pharmaceuticals stock is 1.83 with a target price of $163.29, implying an upside potential of 28.4% over Alexion Pharmaceuticals’ closing price of $127.18 on November 10, 2018.
Market Realist•6 days agoAnalyzing Alexion Pharmaceuticals’ Dicerna Collaboration
In October 2018, Alexion Pharmaceuticals (ALXN) entered a collaboration with Dicerna Pharmaceuticals that provides Alexion exclusive worldwide licenses and development and commercial rights to two molecules for complement-mediated diseases along with an exclusive option for other molecules for two additional targets within the complement pathway. Under the collaboration, Alexion will make an upfront payment of $37.0 million and could be required to pay up to ~$625.0 million in milestone payments and royalties on product sales.
Markit•6 days agoSee what the IHS Markit Score report has to say about Abbott Laboratories.
Abbott Laboratories NYSE:ABT
- Zacks•7 days ago
Abbott (ABT) Gains As Market Dips: What You Should Know
In the latest trading session, Abbott (ABT) closed at $72.96, marking a +0.63% move from the previous day.
Market Realist•7 days agoA Look at Alexion Pharmaceuticals’ Operational Performance
For fiscal 2018 and 2019, Alexion Pharmaceuticals’ gross margins are expected at 91.08% and 91.22%, respectively, as compared with gross margins of 91.95% for fiscal 2017. In comparison, fiscal 2018 gross margins for peers Abbott Laboratories (ABT), Amgen (AMGN), and Johnson & Johnson (JNJ) are expected at 59.29%, 85.73%, and 70.43%, respectively. Alexion Pharmaceuticals incurred selling, general, and administrative expenses of $258.7 million in the third quarter of 2018 as compared with $270.6 million in the third quarter of 2017.
Market Realist•7 days agoHow Alexion Is Positioned in November
Alexion Pharmaceuticals (ALXN), a global biopharmaceutical company, is a leader in complement inhibition and is focused on the therapeutic areas of hematology, nephrology, neurology, and metabolic disorders. Alexion has brought to market the only approved complement inhibitor for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. Further, the company has two enzyme replacement therapies for hypophosphatasia and lysosomal acid lipase deficiency.
Market Realist•7 days agoAnalyzing Alexion Pharmaceuticals’ Product Performance
Alexion Pharmaceuticals’ (ALXN) key products on the market include Soliris, Strensiq, and Kanuma. Total Soliris sales increased from $755.4 million in the third quarter of 2017 to $888.0 million in the latest quarter. Its US sales increased from $307.6 million in the third quarter of 2017 to $404.5 million in the latest quarter. Its Europe sales increased from $248.4 million in the third quarter of 2017 to $262.1 million in the latest quarter.
- CNBC•8 days ago
Cramer's advice on investing during Washington gridlock: Buy fast growers
Jim Cramer recommends stocks like Amazon and Apple in the wake of the 2018 midterm elections, in which Democrats regained control of the House of Representatives.
Markit•8 days agoSee what the IHS Markit Score report has to say about Abbott Laboratories.
Abbott Laboratories NYSE:ABT
- InvestorPlace•13 days ago
5 Income Stocks for Massive Payouts and Steady Growth
Although many investors like to follow equities for potential stock price increases, a large number also choose to focus on income stocks. The average S&P 500 stock dividend yield currently stands at just over 1.9%. Also, it allows for the long-term appreciation gained by investing in S&P 500 equities.
- Zacks•13 days ago
Abbott (ABT) Q3 Earnings Top Estimates
Abbott (ABT) delivered earnings and revenue surprises of 1.35% and -0.12%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Zacks•15 days ago
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
Abbott (ABT) closed the most recent trading day at $69.30, moving +1.91% from the previous trading session.
TechCrunch•17 days agoAnother Kleiner investor has just raised her own fund
According to a newly processed SEC filing, the firm is called Define Ventures, and it has already locked down $50 million in capital commitments from a handful of investors. Chou O'Keefe had joined Kleiner Perkins in 2013 as a partner in its small life sciences group, to focus on digital health and connected devices. Before becoming a VC, she spent six years with Abbott Vascular, a division of the health care giant Abbott, first as a global product manager and later as a global marketing director.
- Reuters•20 days ago
Abbott, AbbVie settle TriCor marketing case for $25 million
The U.S. Justice Department on Friday announced the settlement, which resolves claims first raised in a whistleblower lawsuit filed in federal court in Philadelphia in 2009 by a former Abbott sales representative. AbbVie was spun out of Abbott in 2013.
